Barclays PLC lowered shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) from an overweight rating to a hold rating in a report issued on Wednesday morning. Barclays PLC currently has $19.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $16.00.

A number of other equities analysts also recently commented on the company. Piper Jaffray Companies lifted their target price on Halozyme Therapeutics from $20.00 to $26.00 and gave the company an overweight rating in a research note on Thursday, September 14th. Zacks Investment Research upgraded Halozyme Therapeutics from a hold rating to a buy rating and set a $14.00 target price for the company in a research note on Friday, August 25th. Deutsche Bank AG lifted their target price on Halozyme Therapeutics to $20.00 and gave the company a buy rating in a research note on Friday, September 15th. Canaccord Genuity set a $16.00 target price on Halozyme Therapeutics and gave the company a buy rating in a research note on Wednesday, July 26th. Finally, BidaskClub upgraded Halozyme Therapeutics from a sell rating to a hold rating in a research note on Saturday, August 26th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Halozyme Therapeutics presently has an average rating of Hold and an average price target of $18.13.

Halozyme Therapeutics (NASDAQ:HALO) opened at $18.24 on Wednesday. Halozyme Therapeutics has a 52 week low of $9.68 and a 52 week high of $19.37. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the Zacks’ consensus estimate of $0.06 by ($0.04). Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. The company had revenue of $63.73 million during the quarter, compared to analyst estimates of $58.95 million. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. The business’s revenue was up 100.1% on a year-over-year basis. equities analysts predict that Halozyme Therapeutics will post 0.15 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/halozyme-therapeutics-inc-halo-downgraded-to-hold-at-barclays-plc/1721470.html.

A number of large investors have recently made changes to their positions in HALO. Parametric Portfolio Associates LLC raised its holdings in Halozyme Therapeutics by 37.2% during the first quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock worth $684,000 after purchasing an additional 14,308 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Halozyme Therapeutics by 2.8% during the first quarter. Principal Financial Group Inc. now owns 20,602 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 558 shares in the last quarter. Vanguard Group Inc. raised its holdings in Halozyme Therapeutics by 3.7% during the first quarter. Vanguard Group Inc. now owns 8,763,558 shares of the biopharmaceutical company’s stock worth $113,576,000 after purchasing an additional 311,215 shares in the last quarter. BlackRock Inc. raised its holdings in Halozyme Therapeutics by 7,292.8% during the first quarter. BlackRock Inc. now owns 11,062,842 shares of the biopharmaceutical company’s stock worth $143,374,000 after purchasing an additional 10,913,199 shares in the last quarter. Finally, Credit Suisse AG raised its holdings in Halozyme Therapeutics by 97.2% during the first quarter. Credit Suisse AG now owns 261,374 shares of the biopharmaceutical company’s stock worth $3,386,000 after purchasing an additional 128,861 shares in the last quarter. 83.12% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.